Biotech Values

[DewDiligence]

Comments on new Eliquis data from the PI of the study in question:

http://www.reuters.com/article/2012/12/08/us-blood-pfizer-bloodclots-idUSBRE8B70CL20121208

“Usually when you have an effective antithrombotic you have to pay a price in terms of bleeding. This was not the case in this study,” Dr. Giancarlo Agnelli, the study's principal investigator, said in a telephone interview.

…“Extended treatment [i.e. for one year or longer] might be clinically relevant because the recurrence rate after stopping treatment can be 10 percent in the first year… The next step would be to see whether this clinical benefit is extended after one year [ka-ching!],” Agnelli said.

… It is quite clear that the lower dose [2.5mg BID] is as effective as the higher. For the first time we showed that by reducing the dose of an antithrombotic agent in this clinical setting we can have the same efficacy with no major bleeding," Agnelli said.